FORGOT YOUR DETAILS?

LINK HEALTHCARE OBTAINS AUSTRALIAN ORPHAN DRUG DESIGNATION FOR PASER

by / Monday, 23 February 2015 / Published in News

Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 23/2/15.

Specialist pharmaceutical company, LINK Healthcare (‘LINK’) is pleased to announce Australian orphan drug designation for para-amino salicylic acid (PAS) brand PASER®, indicated for use as part of an appropriate combination therapy for the treatment of multi-drug resistant tuberculosis. PASER® is part of Link’s portfolio through a long term relationship with specialist therapeutic company, Jacobus Pharmaceutical Corp. of Princeton New Jersey (‘JPC’).

LINK has already acquired the marketing authority for PASER® in South Africa and will file an application for registration in Australia and in other markets where the product is urgently required.

Tuberculosis (TB) is a curable disease that continues to kill nearly 1.5 million people across the globe each year. TB is a leading killer of HIV-positive people causing one fourth of all HIV-related deaths. In 2013 an estimated 480,000 people developed multidrug-resistant TB (MDR-TB). MDR-TB is a form of the disease that does not respond to at least two of the primary drugs used to treat the disease. On average, an estimated 9% of people with MDR-TB have Extensively Drug-resistant (XDR-TB) meaning resistance to two of the key drugs used as part of second-line regimens.1, 2

PASER® is most commonly used in patients with MDR-TB or in situations when therapy with isoniazid and rifampicin is not possible due to a combination of resistance and / or intolerance.

Chairman of LINK Healthcare, John Bacon, commented:
“We are pleased to be expanding on our long and successful partnership with Jacobus Pharmaceuticals. We have been working with JPC for more than a decade in Australia and New Zealand and for two years in South Africa. Their products are highly valued for the treatment of difficult diseases such as multi-drug resistant TB and Leprosy. This is an area in which we specialise and we look forward to supplementing the treatment of TB across the region by expanding access to this important product.”
1. WHO Tuberculosis Report 2014. Available from: http://www.who.int/tb/publications/factsheet_global.pdf
2. WHO Tuberculosis Factsheet October 2014. Available from http://www.who.int/mediacentre/factsheets/fs104/en/

 

About LINK Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan)
LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa.

LINK provides exceptional regulatory, sales, marketing, customer-service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.’
The range includes specialist proprietary and in-licensed products sold under the LINK Pharma, LINK Medical Technologies, EQUITY Pharmaceuticals, EQUITY Medical Technologies, HOMEMED & NOVAGEN Pharma brands.

LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.

For more information about LINK Healthcare visit www.linkhealthcare.co

FOR FURTHER INFORMATION
Contact LINK Healthcare on 61 (2) 8401 9777
Corporate and Media Enquiries:
Mr John Bacon
Executive Chairman

TOP